An observational study in Germ Cell Tumor, Metachronous Malignant Neoplasm and Seminoma, sponsored by SWOG Cancer Research Network. Active, not recruiting at 424 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by SWOG Cancer Research Network · Observational
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
PRIMARY OBJECTIVE:
I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy.
SECONDARY OBJECTIVES:
I. To bank prospectively obtained serial liquid biospecimens for low and moderate risk of relapse patients annotated by patient level clinical data.
II. To bank prospectively collected, clinically annotated specimens for high risk patients and non-testicular primary patients in collaboration with Children's Oncology Group study AGCT 1531.
OUTLINE:
Patients undergo collection of blood every 3-6 months for up to 3 years.
63 studies on the registry are indexed under Seminoma; 15 are open to participants now.
Browse Seminoma studies →SWOG Cancer Research Network is the lead sponsor of 339 studies on the registry; 37 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.
Compared within Seminoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms, Germ Cell and Embryonal. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with newly diagnosed germ cell tumor
Inclusion Criteria:
Patients must have beta-human chorionic gonadotropin (beta- HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo collection of blood every 3-6 months for up to 3 years.
Other: Biomarker Analysis · Procedure: Blood Product Collection
Correlative study
Undergo collection of blood
Also known as: Collection, Blood Products
To estimate positive predictive value of miRNA 371 in early stage testicular seminoma and nonseminoma patients
Positive predictive value will be estimated using plasma miRNA 371 expression at relapse.
Time frame: Up to 3 years
To bank blood specimens of patients at low risk and moderate risk of relapse
10 ml whole blood will be collected at time points specified by the protocol.
Time frame: Up to 3 years
Showing the first 100 of 424 sites across 3 countries. Choose a country and city above to see the rest.
Started Jul 2020 (actual). Primary completion is estimated for Jan 2027, 77 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SWOG Cancer Research Network →